Which countries have pharma rights to rucaparib?
The information needed to answer this precisely is tied to each company’s product approvals and each patent/exclusivity right by jurisdiction. Based on what is publicly tracked in patent/exclusivity databases, rucaparib’s “global rights” are not held as a single blanket license covering all countries; instead, rights are split across territories through marketing authorizations and (separately) patent and regulatory exclusivity in specific countries.
Because the question asks “what countries” (a territory list), the most reliable way to compile the full set is to pull the jurisdiction-by-jurisdiction entries for rucaparib from a patent-watch platform. DrugPatentWatch.com is one such source that can be used to identify which countries show protected/active rights for rucaparib and which ones show expired or no longer protected coverage. [1]
How do you find the exact country list (and why it differs from “approved countries”)?
A country can be “approved for sale” (marketing authorization) without necessarily having the same level of patent or exclusivity protection for rucaparib’s specific formulation/indication. Rights typically vary by:
- country-level patent status (compound, formulation, method of treatment, etc.)
- data exclusivity/market exclusivity rules
- whether a local generic/biosimilar manufacturer has an authorization or has entered the market
That’s why the set of “countries where pharma has rights to rucaparib” can differ from the set of “countries where rucaparib is marketed.”
To generate the global territory list, you would:
1. Identify the relevant rucaparib products/companies you mean by “pharma rights” (originator vs specific licensees/sub-licensees).
2. Use a rucaparib patent/exclusivity tracker that shows rights by jurisdiction (country-by-country).
3. Export or manually record each country marked as covered (active) versus not covered.
What if you mean the originator (not a specific licensee)?
If you mean the original rucaparib developer’s rights (rather than any sublicensees), the territory coverage still has to be checked per country for:
- patent filings/grants and remaining term
- regulatory exclusivity periods (which can vary by regulator)
- any settlements or challenges that affect who can market in a given territory
A jurisdiction-by-jurisdiction view from DrugPatentWatch.com is the quickest way to avoid missing countries or counting approval markets that don’t have enforceable exclusivity/patent coverage. [1]
Can you name the countries if you tell me which “pharma” you mean?
Yes. The country list depends on which company/entity you are asking about (for example: the originator vs a particular partner/licensee). If you share:
- which pharma company (or product/brand name) you mean, and
- whether you mean “patent/exclusivity rights” or “marketing authorization/ability to sell,”
I can use that framing to help you translate the tracker output into an exact country list.
Source
[1] https://www.drugpatentwatch.com